Occupational Activity
Novo Nordisk to Cut 9,000 Jobs Globally as New CEO Targets $1.3B Savings by 2026
Novo Nordisk; layoffs; 9000 jobs; cost savings; CEO Doustdar; restructuring; weight-loss drugs; Wegovy; Ozempic; competition; Eli Lilly; profit guidance
Pfizer Veteran Suneet Varma Named CEO of Phase 3-Ready Biotech Startup Intent Biologics
Suneet Varma; Pfizer vet; Intent Biologics; CEO appointment; regenerative medicine; Phase 3 clinical trials; biotech startup; inflammation and immunology
Recent Developments in Logistical Coordination for Decentralized Clinical Trials (DCTs)
Decentralized Clinical Trials; Logistics; FDA Guidance 2024; Remote Patient Monitoring; Supply Chain Management; Digital Trial Platforms
Endpoints News to Announce 2025 ‘Endpoints 11’ Biotechs to Watch Live in Boston
Endpoints 11; biotech startups; biopharma; Boston; live event; industry trends; biotech innovation
How Past Endpoints 11 Winners Fared During the 2025 Biotech Downturn
Endpoints 11; biotech downturn 2025; biotech winners; Xaira Therapeutics; biotech awards; industry trends
Recent News on Scaling Up Cell & Gene Therapy Supply Chains (2025)
cell and gene therapy; supply chain; scalability; logistics; digital solutions; risk mitigation; white glove delivery; patient-specific therapies; automation; market growth
Personalizing Metabolic Care with Digital Twins: Recent Developments
digital twins; metabolic health; AI healthcare; personalized medicine; biomarkers; diabetes management; obesity reversal; real-time guidance; GLP-1; Twin Health
Indivior Initiates Cost-Cutting Plan with Job Cuts and Real-Estate Review
Indivior; job cuts; real-estate; cost-cutting; restructuring; sales guidance; profit guidance; Opvee divestiture; competition; generic drugs
Recent Advances for Confident Cell Line Transfer
cell line development; cell transfer; clone stability; electroporation; transfection; quality assurance; GMP compliance; cell therapy
Nucleus RadioPharma Appoints Former FDA Commissioner Dr. Stephen Hahn as CEO
Nucleus RadioPharma; Stephen Hahn; FDA Commissioner; CEO appointment; radiopharmaceuticals; cancer therapy; supply chain; biotech leadership